ReviewEye (London, England)2018
Cellular regeneration strategies for macular degeneration: past, present and future.
Review in Eye (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 98 citations in OpenAlex.
- Therapeutic potential of mesenchymal stem cells in ocular degenerative disorders.Journal of translational medicine · 2026Review
- Evaluating the outcomes of pluripotent stem-cell-derived photoreceptor transplantation in retinal repair.The FEBS journal · 2025Review
- Veterinary Regenerative Medicine: The Evolving Role of Stem Cell-Based Therapies.Stem cell reviews and reports · 2025Review
- Hormetic Effects of Curcumin in RPE Cells: SIRT1 and Caspase-3 Inactivation with Implications for AMD.International journal of molecular sciences · 2025Article
- Small-Molecule Inhibition of the Hippo Pathway Induces Regeneration of Retinal Pigment Epithelium.Investigative ophthalmology & visual science · 2025Article
- Mesenchymal stem cell therapy in veterinary ophthalmology: clinical evidence and prospects.Veterinary research communications · 2024Review
- Session-by-Session Prediction of Anti-Endothelial Growth Factor Injection Needs in Neovascular Age-Related Macular Degeneration Using Optical-Coherence-Tomography-Derived Features and Machine Learning.Diagnostics (Basel, Switzerland) · 2024Article
- Article
- Review
- Fractal Phototherapy in Maximizing Retina and Brain Plasticity.Advances in neurobiology · 2024Article
- Hyaluronan-CD44 Interaction Regulates Mouse Retinal Progenitor Cells Migration, Proliferation and Neuronal Differentiation.Stem cell reviews and reports · 2023Article
- Assessing the role of T cells in response to retinal injury to uncover new therapeutic targets for the treatment of retinal degeneration.Journal of neuroinflammation · 2023Article
- Cilia-associated wound repair mediated by IFT88 in retinal pigment epithelium.Scientific reports · 2023Article
- Review
- Choroidal Neovascular Membranes in Retinal and Choroidal Tumors: Origins, Mechanisms, and Effects.International journal of molecular sciences · 2023Review
- Editorial: Methods and advances in induced pluripotent stem cells-ophthalmology.Frontiers in cell and developmental biology · 2023Article
- Potential therapeutic strategies for photoreceptor degeneration: the path to restore vision.Journal of translational medicine · 2022Review
- Electronic photoreceptors enable prosthetic visual acuity matching the natural resolution in rats.Nature communications · 2022Article
- Article
- Myeloid cells in retinal and brain degeneration.The FEBS journal · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Despite considerable effort and significant therapeutic advances, age-related macular degeneration (AMD) remains the commonest cause of blindness in the developed world. Progressive late-stage AMD with outer retinal degeneration currently has no proven treatment. There has been significant interest in the possibility that cellular treatments may slow or reverse visual loss in AMD. A number of modes of action have been suggested, including cell replacement and rescue, as well as immune modulation to delay the neurodegenerative process. Their appeal in this enigmatic disease relate to their generic, non-pathway-specific effects. The outer retina in particular has been at the forefront of developments in cellular regenerative therapies being surgically accessible, easily observable, as well as having a relatively simple architecture. Both the retinal pigment epithelium (RPE) and photoreceptors have been considered for replacement therapies as both sheets and cell suspensions. Studies using autologous RPE, and to a lesser extent, foetal retina, have shown proof of principle. A wide variety of cell sources have been proposed with pluripotent stem cell-derived cells currently holding the centre stage. Recent early-phase trials using these cells for RPE replacement have met safety endpoints and hinted at possible efficacy. Animal studies have confirmed the promise that photoreceptor replacement, even in a completely degenerated outer retina may restore some vision. Many challenges, however, remain, not least of which include avoiding immune rejection, ensuring long-term cellular survival and maximising effect. This review provides an overview of progress made, ongoing studies and challenges ahead.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.